We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Cards for Genomic Health (GHDX) in Q4 Earnings?
Read MoreHide Full Article
Genomic Health, Inc. is scheduled to report fourth-quarter and 2017 results on Mar 8, before the market opens.
Last quarter, the company posted a positive earnings surprise of 400%. Moreover, Genomic Health beat the Zacks Consensus Estimate in two of the trailing four quarters, the average being 116.7%.
The fourth-quarter results are expected to show steady growth in Product revenues. Let’s take a look at how things are shaping up prior to this announcement.
Genomic Health’s product-revenue unit continues to make significant progress with its Oncotype DX breast cancer test. Positive results related to Oncotype DX Genomic Prostate Score are also likely to yield solid results in the fourth quarter.
In the third quarter, total product revenues grew 2.1% year over year. Product revenues grew domestically as well as internationally. The Zacks Consensus Estimate for product revenues is pegged at $89 million for the fourth quarter, reflecting 6% growth from the third quarter and 8.5% year over year.
Notably, for the fourth quarter, Genomic Health again expects double-digit test growth at the international business. According to the company, as of Sep 30, 2017, majority of the product revenues has been derived from the sale of one product — the Oncotype DX breast cancer test.
So far, Genomic Health has been witnessing healthy progress with regard to establishing coverage for its Oncotype DX breast cancer test. Also, Genomic Health and Biocartis Group NV had signed an agreement in last September to develop an in vitro diagnostic (IVD) version of the Oncotype DX Breast Recurrence Scoretest on Biocartis' proprietary Idylla platform. The company’s continuous focus to strengthen its position in the niche is likely to boost the top line.
Other Factors at Play
Solid Estimates
The Zacks Consensus Estimate for fourth-quarter 2017 adjusted earnings of 9 cents reflects a 200% rise from the previous quarter and 125% from the year-ago quarter.
The Zacks Consensus Estimate for revenue is pegged at $89 million, showing an increase of 6% from the preceding quarter and 7.2% from the year-ago quarter.
Guidance Strong
The company has reiterated the guidance for 2017. Genomic Health expects to meet the low end of its full-year revenue guidance of $345-$355 million. The Zacks Consensus Estimate of $343.1 million is below the guided range.
Prostate-Cancer Business Drives Growth
Genomic Health’s U.S. prostate cancer business has been consistently improving over the last few quarters. The company has continued to make progress, delivering actionable results to increase adoption of this test and gather evidence to support private reimbursement. In the third quarter, revenues in this business more than doubled on a year-over-year basis with U.S. product revenues being driven by a 139% rise in Prostate test revenues.
Recently, Genomic Health announced a multi-year research collaboration agreement with Janssen Pharmaceuticals. Through this, the companies will evaluate the responsiveness of Genomic Health’s Oncotype DX Genomic Prostate Score test to Janssen’s prostate cancer drug pipeline.
Forex Woes
With a considerable portion of its revenues coming from outside the United States, the company faces the risk of exchange rate fluctuations.
Earnings Whispers
Our proven model does not conclusively show that Genomic Health is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: Genomic Health has an Earnings ESP of 0.00%. This is because the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 9 cents.
Zacks Rank: Genomic Health carries a Zacks Rank #3, which increases the predictive power of ESP. However, an ESP of 0.00% makes surprise prediction difficult.
Stocks to Consider
Here are a few medical stocks worth considering as these have the right combination of elements to post an earnings beat this quarter.
NuVasive, Inc. has an Earnings ESP of +0.51% and a Zacks Rank #3.
Integra LifeSciences Holdings Corporation (IART - Free Report) has an Earnings ESP of +2.66% and a Zacks Rank #3.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
What's in the Cards for Genomic Health (GHDX) in Q4 Earnings?
Genomic Health, Inc. is scheduled to report fourth-quarter and 2017 results on Mar 8, before the market opens.
Last quarter, the company posted a positive earnings surprise of 400%. Moreover, Genomic Health beat the Zacks Consensus Estimate in two of the trailing four quarters, the average being 116.7%.
The fourth-quarter results are expected to show steady growth in Product revenues. Let’s take a look at how things are shaping up prior to this announcement.
Genomic Health, Inc. Price and EPS Surprise
Genomic Health, Inc. Price and EPS Surprise | Genomic Health, Inc. Quote
Product Revenues in Focus
Genomic Health’s product-revenue unit continues to make significant progress with its Oncotype DX breast cancer test. Positive results related to Oncotype DX Genomic Prostate Score are also likely to yield solid results in the fourth quarter.
In the third quarter, total product revenues grew 2.1% year over year. Product revenues grew domestically as well as internationally. The Zacks Consensus Estimate for product revenues is pegged at $89 million for the fourth quarter, reflecting 6% growth from the third quarter and 8.5% year over year.
Notably, for the fourth quarter, Genomic Health again expects double-digit test growth at the international business. According to the company, as of Sep 30, 2017, majority of the product revenues has been derived from the sale of one product — the Oncotype DX breast cancer test.
So far, Genomic Health has been witnessing healthy progress with regard to establishing coverage for its Oncotype DX breast cancer test. Also, Genomic Health and Biocartis Group NV had signed an agreement in last September to develop an in vitro diagnostic (IVD) version of the Oncotype DX Breast Recurrence Scoretest on Biocartis' proprietary Idylla platform. The company’s continuous focus to strengthen its position in the niche is likely to boost the top line.
Other Factors at Play
Solid Estimates
The Zacks Consensus Estimate for fourth-quarter 2017 adjusted earnings of 9 cents reflects a 200% rise from the previous quarter and 125% from the year-ago quarter.
The Zacks Consensus Estimate for revenue is pegged at $89 million, showing an increase of 6% from the preceding quarter and 7.2% from the year-ago quarter.
Guidance Strong
The company has reiterated the guidance for 2017. Genomic Health expects to meet the low end of its full-year revenue guidance of $345-$355 million. The Zacks Consensus Estimate of $343.1 million is below the guided range.
Prostate-Cancer Business Drives Growth
Genomic Health’s U.S. prostate cancer business has been consistently improving over the last few quarters. The company has continued to make progress, delivering actionable results to increase adoption of this test and gather evidence to support private reimbursement. In the third quarter, revenues in this business more than doubled on a year-over-year basis with U.S. product revenues being driven by a 139% rise in Prostate test revenues.
Recently, Genomic Health announced a multi-year research collaboration agreement with Janssen Pharmaceuticals. Through this, the companies will evaluate the responsiveness of Genomic Health’s Oncotype DX Genomic Prostate Score test to Janssen’s prostate cancer drug pipeline.
Forex Woes
With a considerable portion of its revenues coming from outside the United States, the company faces the risk of exchange rate fluctuations.
Earnings Whispers
Our proven model does not conclusively show that Genomic Health is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: Genomic Health has an Earnings ESP of 0.00%. This is because the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 9 cents.
Zacks Rank: Genomic Health carries a Zacks Rank #3, which increases the predictive power of ESP. However, an ESP of 0.00% makes surprise prediction difficult.
Stocks to Consider
Here are a few medical stocks worth considering as these have the right combination of elements to post an earnings beat this quarter.
Universal Health Services (UHS - Free Report) has an Earnings ESP of +1.96% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
NuVasive, Inc. has an Earnings ESP of +0.51% and a Zacks Rank #3.
Integra LifeSciences Holdings Corporation (IART - Free Report) has an Earnings ESP of +2.66% and a Zacks Rank #3.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>